Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.87 |
| ▸ | IDH2 | P48735 | 7/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557108 | 1.00 | IDH1 (0.87) | IDH1IDH2 | |
| SCHEMBL16393283 | 0.96 | IDH1 (0.79) | IDH1IDH2 | |
| SCHEMBL16393075 | 0.96 | IDH1 (0.79) | IDH1IDH2 | |
| SCHEMBL16393257 | 0.93 | IDH1 (1.00) | IDH1IDH2 | |
| SCHEMBL21573412 | 0.88 | IDH1 (0.67) | IDH1IDH2 | |
| SCHEMBL21573439 | 0.87 | IDH1 (0.87) | IDH1IDH2 | |
| SCHEMBL21573335 | 0.87 | IDH1 (0.65) | IDH1IDH2 | |
| SCHEMBL21573307 | 0.86 | IDH1 (0.89) | IDH1IDH2 | |
| SCHEMBL29975808 | 0.86 | IDH1 (0.89) | IDH1IDH2 | |
| SCHEMBL16392938 | 0.86 | IDH1 (0.89) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028961-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028961-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.